



Suite 518, Level 5
165-167 Phillip Street
Sydney NSW Australia 2000
PO Box H100
Australia Square NSW Australia 1215
T +61 2 8098 0819
F +61 2 8080 8315
www.mmjphytotech.com.au
info@mmjphytotech.com.au
ABN 91 601 236 417

ASX RELEASE

13 August 2018

MediPharm Labs Continues to Strengthen Leadership Team for Growth

MMJ PhytoTech Limited (ASX: MMJ) ("MMJ") is pleased to note the attached news release by MediPharm Labs Inc ("MediPharm Labs") confirming the appointment of two key marketing and business development senior management executives.

Investor and Media Enquiries

Jason Conroy
Chief Executive Officer
T +61 2 8098 0819
jconroy@mmjphytotech.com.au

About MMJ

MMJ is a global cannabis investment company. MMJ owns a portfolio of minority investments and aims to invest across the full range of emerging cannabis-related sectors including healthcare, technology, infrastructure, logistics, processing, cultivation, equipment and retail. For MMJ's latest investor presentation and news, please visit: <https://www.mmjphytotech.com.au/investors/>

Source: MediPharm Labs Inc.

August 09, 2018 16:43 ET

MediPharm Labs Continues to Strengthen Leadership Team for Growth

Not for distribution to United States newswire services or for release publication, distribution or dissemination directly, or indirectly, in whole or in part, in or into the United States.

TORONTO, Aug. 09, 2018 (GLOBE NEWSWIRE) -- POCML 4 Inc. (TSXV:POCM.P) ("**POCML**") and MediPharm Labs Inc. ("**MediPharm**" or the "**Company**") are pleased to announce the addition by MediPharm of Sybil Taylor, as the Company's Chief Marketing Officer, and Michael Perron, CPA (USA), MAcc as the Director of Global Business Development. Ms. Taylor was most recently Chief Marketing Officer at Nuuvera Canada. Mr. Perron was most recently a Senior Manager and Cannabis Advisory Lead at MNP LLP.

"Our business is driven by a commitment to quality. The quality of our products, the quality of our facility and, most of all, the quality of our leadership team," said Patrick McCutcheon, President and CEO of MediPharm. "The addition of Sybil and Mike will bring our leadership to a new level of competitive positioning within the industry."

Prior to joining MediPharm, Ms. Taylor has enjoyed a 25-year career bringing premium consumer brands to life by developing innovative customer-focused marketing strategies. She launched Steam Whistle Pilsner in 2000 as a pioneering upstart and helped it grow to the largest craft beer brand in Canada. As Chief Marketing Officer at Nuuvera Canada, Sybil was a senior contributor to this Canadian Cannabis start-up via strategic planning and brand development for medical and recreational brands.

Sybil has been part of c-suite teams in two of *Canada's Best Managed Companies*, and through CSR initiatives, she has brought numerous awards and public profile to her managed brands. Sybil received her Honours Bachelor Business Administration degree from Wilfrid Laurier University.

Mr. Perron brings more than 10 years of professional business advisory experience to the MediPharm leadership team. While at MNP, Mr. Perron has held leadership roles within the firm's management consulting, enterprise risk, and corporate finance practice areas. Mr. Perron most recently served as the advisory lead within MNPs national cannabis practice.

Mr. Perron earned his Masters of Accounting (MAcc) from the University of Southern California, holds a Bachelors of Arts degree from the University of Jamestown, and is a Certified Public Accountant in California.

POCML has entered into a definitive agreement with MediPharm that will govern the previously announced proposed business combination between POCML and MediPharm (the "**Transaction**"). As previously announced, the Transaction will result in a reverse take-over of POCML by the shareholders of MediPharm and is intended to constitute the "Qualifying Transaction" of POCML as such term is defined in the policies of the TSX Venture Exchange.

About MediPharm Labs Inc.

Founded in 2015, MediPharm is a pioneer in the cannabis industry and has the distinction of being the first company in Canada to become a licensed producer for cannabis oil production under the *Access to Cannabis for Medical Purposes Regulations* (ACMPR) without first receiving a cannabis cultivation licence. This expert focus on cannabis concentrates from MediPharm's cGMP (current Good Manufacturing Practices) and ISO standard clean rooms and critical environments laboratory, allows MediPharm to work with its established, Health Canada-approved cultivation partners to produce pharmaceutical-grade cannabis oil with a competitive advantage. MediPharm is research-driven and focused on downstream secondary extraction methodology, distillation, and cannabinoid isolation and purification. MediPharm provides B2B contract processing of cannabis to Canadian authorized licensed producers and appropriate international growers, supplying integrity-assured cannabis oil to qualified companies for sale under their own brand. In addition, MediPharm will supply raw materials, formulations, processing and packaging for the creation of ready-to-sell advanced derivative products. Through its subsidiary, MediPharm Labs Australia Pty. Ltd., MediPharm has also completed its application process with the federal Office of Drug Control to extract and import medical cannabis products in Australia.

For additional information about MediPharm, please see MediPharm's website:
www.medipharmlabs.com

For Additional Information:

Pat McCutcheon, President and CEO, MediPharm Labs Inc.

investors@medipharmlabs.com

(705) 719-7424

David D'Onofrio, Chief Executive Officer, Chief Financial Officer, Secretary and Director,
POCML 4 Inc.

ddonofrio@poweronecapital.com

(416) 643-3880

NEITHER THE TSXV NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSXV) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION:

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, to the terms and conditions of the proposed Transaction. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements.

Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; and the delay or failure to receive board, shareholder or regulatory approvals. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, POCML and MediPharm assume no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.